News

Discover our binding kinetics platform at Biospain 2016

 Sept, 28-30th  2016

Enzymlogic is attending the 8th international meeting on biotechnology that will be held in Bilbao, Spain, on September 28th to 30th, 2016.


Enzymlogic Kinase and GPCR drug discovery services presented at Biospain

Biospain is the largest biotech event organized by a national bioindustry association (ASEBIO) in Europe, attracting more than 850 companies and investors from 37 countries. As a company working closely with its customers to help them identify inhibitors with novel modes of binding, we see Biospain as an excellent opportunity to share innovative perspectives on the latest strategies used in drug discovery research and add value to our customers business.

Additionally, we will present in this event our offer of binding kinetics and kinetic selectivity services. Enzymlogic’s binding kinetics platform guides the kinetic optimization of drug candidates and accelerates the drug discovery process by withdrawing ineffective or unsafe molecules earlier in the drug discovery process. Our exclusive platform is oriented to biotechnological and pharmaceutical companies, institutions and research groups. 

Don’t miss the opportunity to meet us in person and learn how our drug discovery services can bring you and your business great competitive advantage. If you would like to arrange a one-to-one meeting with our team during the conference, please contact us here.


About Enzymlogic

Enzymlogic offers in vitro biochemical and cell-based assays to the biotechnological and pharmaceutical companies, life science laboratories and academic groups. Our binding kinetics, kinetic selectivity, assay development, profiling and screening services enable faster and cost-effective drug discovery by identifying the most promising drug candidates as well as withdrawing those compounds likely to fail in pre-clinical development. Additionally, Enzymlogic’s pioneering approach provides predictive tools that deliver physiologically relevant insights earlier in the drug discovery process.

Back